Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Single-arm, Self-controlled, Multi-center Phase 3 Study to Compare the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal

Next Previous
X
Search
Trial Profile

An Open, Single-arm, Self-controlled, Multi-center Phase 3 Study to Compare the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iodine radioactive (Primary) ; Recombinant human thyroid stimulating hormone-Suzhou Zelgen Biopharmaceuticals (Primary)
  • Indications Carcinoma; Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Suzhou Zelgen Biopharmaceuticals

    • Most Recent Events

    • 27 Mar 2024 Status changed from active, no longer recruiting to completed.
    • 22 Mar 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
    • 22 Mar 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top